Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 15/20 | 0.57 |
| ▸ | PPARD | Q03181 | 7/20 | 0.57 |
| ▸ | TP53 | P04637 | 1/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.55 |
| ▸ | PPARG | P37231 | 6/20 | 0.53 |
| ▸ | PSEN1 | P49768 | 2/20 | 0.53 |
| ▸ | PSEN2 | P49810 | 2/20 | 0.53 |
| ▸ | APH1B | Q8WW43 | 2/20 | 0.53 |
| ▸ | NCSTN | Q92542 | 2/20 | 0.53 |
| ▸ | APH1A | Q96BI3 | 2/20 | 0.53 |
| ▸ | PSENEN | Q9NZ42 | 2/20 | 0.53 |
| ▸ | RAF1 | P04049 | 1/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24598578 | 0.82 | TP53 (0.60) | PPARAPPARDTP53KDM4EALDH1A1 | |
| SCHEMBL30370993 | 0.82 | CTSD (0.55) | PPARAPPARDPPARGPSEN1PSEN2 | |
| SCHEMBL24598450 | 0.82 | TP53 (0.63) | TP53KDM4EALDH1A1POLB | |
| SCHEMBL24073620 | 0.82 | CTSD (0.55) | PPARAPPARDPPARGPSEN1PSEN2 | |
| SCHEMBL10712777 | 0.82 | PPARA (0.54) | PPARAPPARDPPARGPSEN1PSEN2 | |
| SCHEMBL27342126 | 0.80 | LMNA (0.72) | TP53KDM4EALDH1A1POLB | |
| SCHEMBL31743092 | 0.80 | LMNA (0.72) | TP53KDM4EALDH1A1POLB | |
| SCHEMBL4070406 | 0.77 | CFTR (0.62) | PPARAPPARDKDM4EALDH1A1PPARG | |
| SCHEMBL24801418 | 0.76 | TP53 (0.63) | TP53KDM4EALDH1A1POLB | |
| SCHEMBL17339394 | 0.76 | PPARA (0.65) | PPARAPPARDPPARGPSEN1PSEN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240207267-A1 | (R)-Glutarimide CRBN Ligands and Methods of Use | BEIGENE SWITZERLAND GMBH (CH) | 2024-06-27 | — | — | US | disclosed |
| US-20240207267-A1 | (R)-Glutarimide CRBN Ligands and Methods of Use | BEIGENE SWITZERLAND GMBH (CH) | 2024-06-27 | — | — | US | disclosed |
| WO-2022268052-A9 | (R) -GLUTARIMIDE CRBN LIGANDS AND METHODS OF USE | BEIGENE, LTD. (KY) | 2023-08-17 | — | — | WO | disclosed |
| WO-2022268052-A1 | (R) -GLUTARIMIDE CRBN LIGANDS AND METHODS OF USE | BEIGENE, LTD. (KY) | 2022-12-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240207267-A1 | (R)-Glutarimide CRBN Ligands and Methods of Use | CRBN, CDR2, CRKL | PPARA 3666/4885PPARD 3296/4885TP53 364/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.